Noradrenergic Drug Market Size

  • Report ID: 3817
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Noradrenergic Drug Market Size

Noradrenergic Drug Market size was valued at USD 16.55 Billion in 2023 and is expected to reach USD 23.7 Billion by the end of 2036, expanding at around 2.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of noradrenergic drug is assessed at USD 16.97 Billion.  The growth of the market can be attributed to the growing prevalence of mental disorders across the globe. Norepinephrine drugs are used to treat the symptoms of different mental health issues. These drugs control the body's levels of neurotransmitters and increase alertness and concentration. According to estimates, more than 7% of Indians suffer from some mental disorder.

 In addition to these, factors that are believed to fuel the market growth of noradrenergic drugs include the rising lifestyle disorders. For instance, high-stress conditions can lead to several disorders such as anxiety, depression, blood pressure, and cardiovascular diseases. Noradrenaline drugs can be utilized to treat anxiety and depression. Further, mood and attentiveness are all impacted by norepinephrine. Additionally, the growing prevalence of Attention-deficit/hyperactivity disorder (ADHD) is predicted to present the potential for market expansion over the projected period.


Noradrenergic Drug Market demand
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3817
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of noradrenergic drug is assessed at USD 16.97 Billion.

The noradrenergic drug market size was valued at USD 16.55 Billion in 2023 and is expected to reach USD 23.7 Billion by the end of 2036, expanding at around 2.8% CAGR during the forecast period i.e., between 2024-2036. Growing prevalence of autism, and surging incidences of hypertension are the major factors driving the market growth.

Asia Pacific is likely to dominate majority industry share by 2036, attributed to increasing popularity of antidepressants among the adult population in the region.

Baxter International, Inc., Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample